Subject(s)
Lupus Erythematosus, Systemic , Thrombotic Microangiopathies , Humans , Complement Inactivating Agents/therapeutic use , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy , Thrombotic Microangiopathies/drug therapy , Thrombotic Microangiopathies/etiologySubject(s)
Acute Kidney Injury/etiology , Autoimmune Diseases/complications , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/complications , Glomerulonephritis/complications , Nephrotic Syndrome/etiology , Proteinuria/etiology , Adult , Autoimmune Diseases/diagnosis , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Autoimmune Diseases/therapy , Basement Membrane/immunology , Combined Modality Therapy , Diagnosis, Differential , Female , Glomerulonephritis/diagnosis , Glomerulonephritis/drug therapy , Glomerulonephritis/immunology , Glomerulonephritis/therapy , Humans , Hypertension/complications , Immunosuppressive Agents/therapeutic use , Kidney/pathology , Kidney Glomerulus/immunology , Methylprednisolone/therapeutic use , Obesity, Morbid/complications , Plasmapheresis , Smoking/adverse effectsABSTRACT
BACKGROUND: Transplantation offers an excellent option for patients with immunoglobulin-A nephropathy (IgAN) with severe renal dysfunction. However, IgAN frequently recurs in allografts treated with azathioprine. We examined the impact of mycophenolate mofetil immunosuppression on recurrence of IgAN. METHODS: We reviewed the charts of patients transplanted for IgAN at our institution in the cyclosporin era. Patients were excluded from further analysis if follow-up was <12 months or if immunosuppression at engraftment did not include azathioprine or mycophenolate mofetil. Laboratory data, medications and allograft biopsy findings were compiled. RESULTS: 152 kidney transplantations met the study criteria. At engraftment, 61 allografts were treated with azathioprine and 91 with mycophenolate mofetil. By 3 years post-transplant, IgAN developed in six of 60 (10.0%) azathioprine-treated allografts and five of 62 (8.1%) mycophenolate mofetil-treated allografts (P = 0.76). Overall, 13 azathioprine-treated and seven mycophenolate mofetil-treated allografts showed recurrence. As expected in this retrospective study, the duration of observation was longer in the azathioprine group. The interval between engraftment and diagnosis of recurrent disease was also longer. Survival of allografts with recurrent IgAN was similar in the two groups. Survival of allografts with recurrent IgAN was worse than for allografts without recurrence or allografts transplanted into patients with non-IgAN renal failure. Neither switching azathioprine to mycophenolate mofetil nor using an angiotensin-converting enzyme inhibitor or angiotensin-II type 1 receptor blocker ameliorated the clinical course after a biopsy documented recurrent IgAN. CONCLUSIONS: Mycophenolate mofetil, compared with azathioprine, did not lessen the recurrence of IgAN or its clinical impact.
